TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.1% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price fell 4.1% on Friday . The stock traded as low as $82.50 and last traded at $81.5290. 68,225 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 1,027,063 shares. The stock had previously closed at $85.04.

Analyst Upgrades and Downgrades

TMDX has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Friday. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $124.18.

TransMedics Group Stock Performance

The business’s fifty day moving average is $81.73 and its two-hundred day moving average is $90.63. The stock has a market capitalization of $2.79 billion, a PE ratio of 20.73 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same quarter last year, the business earned $0.92 EPS. TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, research analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently modified their holdings of the stock. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group during the third quarter worth $29,000. Allworth Financial LP raised its stake in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. Parallel Advisors LLC lifted its holdings in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares during the last quarter. Ascentis Independent Advisors bought a new stake in shares of TransMedics Group in the 1st quarter worth about $30,000. Finally, North Star Investment Management Corp. purchased a new position in shares of TransMedics Group during the 1st quarter worth about $30,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.